What changed from existing technology?
This paper explains why involving pathologists early in cancer trials is important for making sure the trials are feasible and the results are reliable.
The paper highlights the importance of early pathology input in cancer trials, which is not commonly emphasized in current trial design practices.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
athology is central to many biologically driven cancer clinical trials. Biomarker-led and translational studies depend on robust tissue pathways, cellular and molec
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Early pathology input can improve the feasibility and reliability of cancer trials by ensuring proper specimen handling and assay selection.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.